Acutaas Chemicals Analyst Review 2027: Profit Jumps 71% and Guidance Rises to 30% Growth
- November 19, 2026
- Posted by: Kunal Singla
- Category: Market
Acutaas Chemicals Stock Snapshot (18 Nov 2026 close)
- Current Market Price (CMP): ₹3,991.30
- 52-Week High / Low: ₹4,130.00 / ₹1,570.00
- Market Capitalisation: ₹32,712 crore
- P/E Ratio vs Industry P/E: 74.6 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹436.9 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹123.1 crore
Quick Answer: The Acutaas Chemicals analyst review 2027 shows a strong quarter and a stock near its high. Q2 FY27 revenue rose about 42.7% to ₹436.9 crore, EBITDA rose about 84.6% to ₹176 crore at a 40.3% margin, and profit rose about 71.4% to ₹123.1 crore. Management raised FY27 revenue growth guidance to about 30% from 25%. PL Capital has a Buy rating with a ₹4,693 target from October 2026, about 18% above the ₹3,991.30 close. At about 75 times earnings, the Acutaas share price target 2027 depends on that growth holding.
The Acutaas Chemicals analyst review 2027 covers the Surat-based maker of advanced pharmaceutical intermediates and specialty chemicals, known as Ami Organics until its renaming. It supplies building blocks that drug makers turn into active ingredients across several therapy areas. Investors searching for an Acutaas share price target 2027 will find a named brokerage target above the current price.
Acutaas Chemicals closed at ₹3,991.30 on 18 November 2026, about 3% below its 52-week high of ₹4,130 and about 2.5 times its low of ₹1,570. This Acutaas Chemicals analyst review 2027 explains the brokerage view, the September quarter and what will shape the Acutaas stock outlook 2027.
Click Here – Get Free Investment Predictions
What Brokerages Say in the Acutaas Chemicals Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| PL Capital (Prabhudas Lilladher) | Buy | ₹4,693 | October 2026, after Q2 FY27 |
| PL Capital (Prabhudas Lilladher) | Buy (upgraded from Accumulate) | ₹3,790 | July 2026 |
| Kotak Securities | Reduce (downgraded from Buy) | Not disclosed in summary | July 2026 |
PL Capital lifted its target to ₹4,693 after the September quarter, valuing the stock at 53 times estimated September 2029 earnings. In July 2026 the same brokerage had upgraded the stock to Buy with a ₹3,790 target. The new target implies about 18% upside from ₹3,991.30.
Kotak Securities took the opposite view in July 2026, downgrading the stock to Reduce despite strong Q1 results, a call driven by valuation. The split shows the core debate in the Acutaas Chemicals analyst review 2027: the business is executing well, but the price already assumes much of that growth.
Q2 FY27 Results in the Acutaas Chemicals Analyst Review 2027
| Quarter | Total Income | EBITDA | Net Profit |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹442.02 crore | ₹181.07 crore | ₹123.14 crore |
| Jun 2026 (Q1 FY27) | ₹331.47 crore | ₹114.87 crore | ₹74.99 crore |
| Mar 2026 (Q4 FY26) | ₹443.86 crore | ₹194.62 crore | ₹134.28 crore |
| Dec 2025 (Q3 FY26) | ₹397.88 crore | ₹155.35 crore | ₹106.22 crore |
| Sep 2025 (Q2 FY26) | ₹316.04 crore | ₹105.16 crore | ₹71.86 crore |
Revenue from operations rose about 42.7% to ₹436.9 crore. Company-reported EBITDA rose about 84.6% to ₹176 crore, and the margin expanded to 40.3% from 31.1%. Net profit rose about 71.4% to ₹123.1 crore. Advanced intermediates brought in about ₹402 crore and specialty chemicals about ₹35 crore.
First-half revenue rose about 49.3% to ₹766.6 crore. The stock rose about 14.5% on 27 October, the day results came out. For the Acutaas Chemicals analyst review 2027, the quarter confirmed that margins can stay near 40% as volumes grow.
How Acutaas Chemicals Makes Money
Acutaas sells chemical intermediates to pharmaceutical and specialty chemical companies in India and abroad.
- Advanced intermediates: complex molecules that drug makers use to produce active pharmaceutical ingredients. This is about 92% of Q2 revenue.
- CDMO: contract development and manufacturing for innovator companies, the fastest-growing part of the business.
- Specialty chemicals: electrolyte additives and other niche chemicals.
Revenue rose from about ₹725 crore in FY24 to ₹1,024 crore in FY25 and ₹1,381 crore in FY26. Profit grew faster, from ₹49 crore to ₹160 crore and then ₹356 crore. Operating cash flow was about ₹292 crore in FY26. That compounding is the foundation of the Acutaas Chemicals analyst review 2027.
Growth Triggers in the Acutaas Chemicals Analyst Review 2027
- Higher guidance: FY27 revenue growth guidance raised to about 30% from 25%.
- CDMO target: CDMO revenue expected to cross ₹1,000 crore in FY27 and reach ₹2,000 crore by FY30.
- Capex: about ₹300 crore of FY27 capex adds capacity.
- Net cash: about ₹301 crore of net cash at 30 September 2026, with debt to equity near zero.
- High returns: return on equity of about 23.6% supports the Acutaas share price target 2027 case.
Key Risks in the Acutaas Chemicals Analyst Review 2027
- Rich valuation: a P/E near 75 against an industry figure of about 40.
- Working capital: working capital rose to 115 days in Q2 from 99 days in Q1 as debtor days grew.
- Customer concentration: a few molecules and customers drive a large share of sales.
- Lumpy quarters: Q1 FY27 profit was ₹75 crore against ₹134 crore in Q4 FY26.
- Mixed brokerage views: one Reduce call sits against Buy ratings in the Acutaas Chemicals analyst review 2027.
Compare Acutaas Chemicals With Other Specialty Chemical Stocks on the Univest Screener
Acutaas Chemicals Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (18 Nov 2026 close) | ₹3,991.30 |
| 52-Week High / Low | ₹4,130.00 / ₹1,570.00 |
| Market Capitalisation | ₹32,712 crore |
| P/E (TTM) vs Industry | 74.6 vs 40.1 |
| Price to Book | 17.61 |
| Book Value per Share | ₹226.87 |
| Return on Equity | 23.64% |
| Debt to Equity | 0.01 |
| EPS (TTM) | ₹53.58 |
| FY26 Revenue / Net Profit | ₹1,381 crore / ₹356 crore |
Price to book value of about 17.6 and a P/E near 75 put Acutaas well above most listed chemical peers on valuation. In the Acutaas Chemicals analyst review 2027, that premium rests on 30% growth and 40% margins continuing for several years.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 32.66% | 32.66% | No change |
| Foreign Investors (FII) | 16.85% | 22.62% | Up 5.77 pts |
| Domestic Institutions (DII) | 22.59% | 19.40% | Down 3.19 pts |
| Public | 27.91% | 25.32% | Down 2.59 pts |
The promoter group holds 32.66%, led by Nareshkumar Patel at 17.69% and Chetankumar Vaghasia at 14.97%. Foreign investors added about 5.8 points over the year, while domestic institutions trimmed. Rising foreign ownership is a notable signal in the Acutaas Chemicals analyst review 2027.
What to Watch After the Acutaas Chemicals Analyst Review 2027
- Full-year growth: delivery of about 30% revenue growth in FY27.
- Margins: whether EBITDA margin holds near 40%.
- CDMO revenue: progress towards ₹1,000 crore this year.
- Working capital: a fall back from 115 days.
- Target revisions: any move from other brokerages would reset the Acutaas share price target 2027.
Final Word on the Acutaas Chemicals Analyst Review 2027
The Acutaas Chemicals analyst review 2027 shows a fast-growing, debt-free intermediates maker with 40% margins, raised guidance and a Buy target about 18% above the price. The valuation is high, and one brokerage has a Reduce call on that basis.
The Acutaas stock outlook 2027 depends on CDMO growth, margin stability and working capital. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Acutaas Chemicals analyst review 2027 show?
It shows strong growth and raised guidance. Q2 FY27 revenue rose about 42.7% to ₹436.9 crore and profit rose about 71.4% to ₹123.1 crore. EBITDA margin reached 40.3%. FY27 revenue growth guidance was raised to about 30%.
What is the Acutaas share price target 2027 from brokerages?
PL Capital has a Buy rating with a ₹4,693 target from October 2026. That implies about 18% upside from the ₹3,991.30 close on 18 November 2026. Kotak Securities downgraded the stock to Reduce in July 2026.
Is Acutaas Chemicals the same as Ami Organics?
Yes, Acutaas Chemicals is the new name of Ami Organics. It makes advanced pharmaceutical intermediates and specialty chemicals. FY26 revenue was about ₹1,381 crore and profit about ₹356 crore.
How does Acutaas Chemicals make money?
It sells pharma intermediates, CDMO services and specialty chemicals. Advanced intermediates were about ₹402 crore of Q2 revenue. CDMO revenue is targeted above ₹1,000 crore in FY27.
Is Acutaas stock expensive based on the Acutaas Chemicals analyst review 2027?
The P/E of about 75 is well above the industry figure of about 40. Price to book is about 17.6. Return on equity is about 23.6% and the company has net cash.
What risks does the Acutaas Chemicals analyst review 2027 highlight?
The main risks are valuation, working capital and customer concentration. Working capital rose to 115 days in Q2 from 99 days. Kotak Securities has a Reduce rating on valuation grounds.
What should investors track after the Acutaas Chemicals analyst review 2027?
Track delivery of about 30% revenue growth in FY27. Watch whether EBITDA margin stays near 40%. CDMO revenue progress towards ₹1,000 crore is another key test.